Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.55 |
| ▸ | KMO | O15229 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | VCP | P55072 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21852321 | 0.88 | MEN1 (0.56) | KDM1AMAPTKMT2AMEN1LMNA | |
| SCHEMBL4937005 | 0.84 | DHODH (0.56) | KDM1AKMT2AMEN1CSNK2A2CSNK2B | |
| SCHEMBL5032528 | 0.84 | KDM1A (0.51) | KDM1AMAPTALOX5KMT2AMEN1 | |
| SCHEMBL525682 | 0.84 | KDM1A (0.76) | KDM1AMAPTALOX5VCPKMT2A | |
| SCHEMBL2870272 | 0.82 | KDM1A (0.78) | KDM1AMAPTALOX5KMT2AMEN1 | |
| SCHEMBL2285389 | 0.79 | AMY1A (0.60) | KDM1AMAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5218680 | 0.78 | KDM1A (0.56) | KDM1AMAPTKMT2AMEN1LMNA | |
| SCHEMBL525812 | 0.78 | KDM1A (0.56) | KDM1AMAPTALOX5KMT2AMEN1 | |
| SCHEMBL5200233 | 0.78 | MAPT (0.68) | KDM1AMAPTALOX5KMT2AMEN1 | |
| SCHEMBL4919827 | 0.78 | KDM1A (0.76) | KDM1AMAPTKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513430-B2 | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-20 | — | — | US | claimed |
| WO-2012015715-A1 | SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-02-02 | — | — | WO | claimed |
| EP-3645531-A1 | THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2020-05-06 | — | — | EP | disclosed |
| US-20200123147-A1 | THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-04-23 | — | — | US | disclosed |
| WO-2019002074-A1 | THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-01-03 | — | — | WO | disclosed |
| US-8513430-B2 | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120029029-A1 | SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2012015715-A1 | SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123147-A1 | THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | KDM1A 162/4885KMO 2766/4885MAPT 3674/4885 |
| US-20120029029-A1 | SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS | HSD11B1, HSD11B2, HSD3B1 | KDM1A 2509/4885KMO 657/4885MAPT 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.